Morgan Stanley Upgrades Dr. Reddy's Labs (RDY) to Overweight
More News related to RDY
- Dr. Reddy's Q2 FY10 Results
- Dr. Reddy's to release Q2 FY10 results on Oct 23, 2009; Earnings call slated for Oct 23, 6.00 PM IST / 8.30 AM EST
- Morgan Stanley Upgrades Dr. Reddy's Labs (RDY) to Overweight
- AMRI Files New Patent Infringement Lawsuits against Dr. Reddy's Laboratories (RDY) and Sandoz
- Pozen (POZN) Receives Notice from Dr. Reddy's Labs (RDY) Indicating Dr. Reddy's has Filed an ANDA to Market a Generic Version of Treximet
More News related to Upgrades
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
Morgan Stanley upgrades Dr. Reddy's Labs (NYSE: RDY) from Equalweight to Overweight.
Morgan analyst says, "...investors may be "underappreciating" the company's upcoming products for U.S. markets."
To see more analyst ratings on RDY Click Here.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company.
Related Categories
UpgradesStocks Mentioned
-0.08Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
